ClinicalTrials.gov record
Recruiting Phase 1 Interventional

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory Acute Myeloid Leukemia (AML ) as a Bridge to Allogeneic Stem Cell Transplant

ClinicalTrials.gov ID: NCT06197672

Public ClinicalTrials.gov record NCT06197672. Field values are reproduced from the official study page; the official ClinicalTrials.gov record remains the source of truth for eligibility, enrollment, and contact information.

ClinicalTrials.gov public records Last synced Apr 29, 2026, 8:48 AM EDT

Data is sourced from official ClinicalTrials.gov public API records. Always review the official ClinicalTrials.gov record for the latest information.

Official title

Chimeric Antigen Receptor T Cell Redirected to Target CD4 Positive Relapsed Refractory AML as a Bridge to Allogeneic Stem Cell Transplant

Study identification

NCT ID
NCT06197672
Recruitment status
Recruiting
Study type
Interventional
Phase
Phase 1
Lead sponsor
Huda Salman
Other
Enrollment
30 participants

Conditions and interventions

Interventions

  • CD4CAR Biological

Biological

Eligibility (public fields only)

Age range
12 Years and older
Sex
All
Healthy volunteers
Healthy volunteers not accepted

This page does not interpret eligibility. Detailed inclusion and exclusion criteria are on the official ClinicalTrials.gov record.

Study timeline

Start date
Mar 18, 2024
Primary completion
Dec 30, 2027
Completion
Dec 30, 2042
Last update posted
Jan 21, 2026

2024 – 2042

United States locations

U.S. sites
4
U.S. states
3
U.S. cities
3
Facility City State ZIP Site status
University of Miami Sylvester Comprehensive Cancer Center Miami Florida 33136 Recruiting
Indiana University Melvin and Bren Simon Comprehensive Cancer Center Indianapolis Indiana 46202 Recruiting
Riley Hospital for Children Indianapolis Indiana 46202 Recruiting
The University of Texas MD Anderson Cancer Center Houston Texas 77030 Recruiting

Site contact phone numbers, emails, and investigator names are intentionally not displayed here. Open the official ClinicalTrials.gov record for site contact information.

About this trial record page

What this page shows
Public field values for ClinicalTrials.gov record NCT06197672, including study identification, conditions, interventions, eligibility (age, sex, healthy volunteer), timeline, and U.S. site list.
What this page does not do
No medical advice, eligibility judgments, treatment recommendations, study quality scoring, or AI-generated medical summaries. No site contact phone numbers, emails, or investigator names.
Where the data comes from
Sourced from the official ClinicalTrials.gov public API. The official record is the source of truth.
Last refresh
Last update posted Jan 21, 2026 · Synced Apr 29, 2026

Related: full search, browse by condition, browse by drug or therapy, browse by sponsor, browse by U.S. city.

Open the official record

The complete protocol, eligibility criteria, and contact information for NCT06197672 live on ClinicalTrials.gov.

View official ClinicalTrials.gov record →